The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure

This study aims to assess the effect of glucagon-like peptide-1 on cardiac output and transpulmonary gradient in patients undergoing right heart catheterisation for clinical reasons.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Papworth Hospital NHS Foundation Trust

Papworth Everard, CB23 3RE, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age over 18
Able to give informed consent
On the waiting list for heart transplant
Left Ventricular Dysfunction awaiting catheterisation

Exclusion criteria

Nicorandil, glibenclamide, Dipeptidyl Peptidase-4 inhibitor, Glucagon-Like Peptide-1 receptor agonist or insulin
Women of child bearing age and breast feeding women
Cardiac pacemaker or other implanted metallic device
Unable to give informed consent

Treatment and study plan

Glucagon-Like Peptide 1

Drug

Primary outcomes

Change in Pulmonary Vascular Resistance with Glucagon-Like Peptide-1

Time frame: 30 minutes

Sponsors and collaborators

Lead sponsor

Papworth Hospital NHS Foundation Trust

Other Gov

Registry information

Important dates

Study start: 2014
Primary completion: 2016
Study completion: 2016
First posted: May 2, 2014
Registry last updated: Apr 5, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed